ライフサイエンスコーパス: malignant melanoma

1 portant environmental factor associated with malignant melanoma.

2 ors that may exhibit histologic overlap with malignant melanoma.

3 s occurred, representing 33% of all incident malignant melanoma.

4 c signaling in the majority of patients with malignant melanoma.

5 significantly reflects mutation frequency in malignant melanoma.

6 tor for CCL1, is strongly expressed by human malignant melanoma.

7 tial therapeutic strategies for treatment of malignant melanoma.

8 raging for applications in breast cancer and malignant melanoma.

9 stulated to contribute to the elimination of malignant melanoma.

10 L ULBP2 as strong prognostic marker in human malignant melanoma.

11 dramatic clinical responses in patients with malignant melanoma.

12 oH2A (mH2A) suppresses tumour progression of malignant melanoma.

13 forming the prognosis for many patients with malignant melanoma.

14 g established in vitro and in vivo models of malignant melanoma.

15 utical for treating patients with metastatic malignant melanoma.

16 V1 may function as an antimetastatic gene in malignant melanoma.

17 B-p53 interaction as a strategy for treating malignant melanoma.

18 several human malignancies, including human malignant melanoma.

19 n cancer, breast cancer, bladder cancer, and malignant melanoma.

20 (18)F-labeled probe for PET of MC1R-positive malignant melanoma.

21 nctions as a "lineage addiction" oncogene in malignant melanoma.

22 tion and restoring wild-type p53 function in malignant melanoma.

23 ients with macroscopic nodal metastases from malignant melanoma.

24 e cancer/testis Ag NY-ESO-1 in patients with malignant melanoma.

25 development of bortezomib and IFN-alpha for malignant melanoma.

26 H(Arg(11)) an ideal candidate for the PET of malignant melanoma.

27 ives rise to genomically unstable progeny in malignant melanoma.

28 invasive ductal carcinoma of the breast, and malignant melanoma.

29 nt, and has been described as an oncogene in malignant melanoma.

30 nevi represents an important risk factor for malignant melanoma.

31 ge and identify treatments for patients with malignant melanoma.

32 (PET) imaging would aid in the detection of malignant melanoma.

33 porter and chemoresistance mediator in human malignant melanoma.

34 cs and targeting therapies for patients with malignant melanoma.

35 be useful for the treatment of patients with malignant melanoma.

36 ignificant antitumor responses in a model of malignant melanoma.

37 play an important role in the progression of malignant melanoma.

38 a valuable prognostic tool for management of malignant melanoma.

39 l treatment of completely resected high-risk malignant melanoma.

40 lanocytic lesions, only some of which become malignant melanoma.

41 iptional inactivation of the RASSF1A gene in malignant melanoma.

42 y resected stage IIB and stage III cutaneous malignant melanoma.

43 , has been observed in highly aggressive and malignant melanoma.

44 recently been discovered as driver events in malignant melanoma.

45 ed as exposures, and the primary outcome was malignant melanoma.

46 on factor FOXM1 is elevated and activated in malignant melanoma.

47 y a combination of rFVIIa and factor F(X) in malignant melanoma.

48 thane extract of W. tinctoria leaves against malignant melanoma.

49 statistically significant increased risk of malignant melanoma.

50 valuated as a chemotherapeutic agent against malignant melanoma.

51 f a pathway implicated in the development of malignant melanoma.

52 for the H2A.Z isoform H2A.Z.2 as a driver of malignant melanoma.

53 RSK signaling and increased cell survival in malignant melanoma.

54 AC inhibition may thus be key to treating malignant melanoma.

55 ic agent for PET and radionuclide therapy of malignant melanoma.

56 nt aetiological factor in the development of malignant melanoma.

57 rgeted treatment strategies are required for malignant melanoma.

58 inding benzamide in patients with metastatic malignant melanoma.

59 e ionotropic glutamate receptors, GRIN2A, in malignant melanoma.

60 lecular determinants of cytoarchitecture, in malignant melanoma.

61 notropic glutamate receptor signaling has in malignant melanoma.

62 S100B is a prognostic marker for malignant melanoma.

63 sence and functional implications of IgG4 in malignant melanoma.

64 trategy for challenging environments such as malignant melanoma.

65 des a genetic approach to predict outcome in malignant melanomas.

66 rst description of chromothripsis in primary malignant melanomas.

67 xpressed by both benign melanocytes and many malignant melanomas.

68 ism of regulation of MITF in melanocytes and malignant melanomas.

69 (also known as BRAF) are found in 50-70% of malignant melanomas.

70 inhibited by Ca(2+)-binding S100 proteins in malignant melanomas.

71 breast cancers, 4/20 neuroblastomas and 4/15 malignant melanomas.

72 of recurrent low-grade gliomas and advanced malignant melanomas.

73 that this gene is epigenetically silenced in malignant melanomas.

74 or the regulation of MITF in melanocytes and malignant melanomas.

75 ion (V600E) is found in more than 50% of all malignant melanomas.

76 as pain, inflammation, airway diseases, and malignant melanomas.

77 95% CI 1.19-1.30), rectum (1.14, 1.07-1.22), malignant melanoma (1.32, 1.24-1.40), breast (1.17, 1.15

78 s (24/32), basal cell carcinomas (30/31) and malignant melanomas (15/15), and provide evidence for a

79 5 sebaceous cell carcinomas [31.25%], and 4 malignant melanomas [25%]) were included in the study.

80 We compared 10 patients who died of malignant melanoma 3.7 years (median, range 0.9-7.6 year

81 me in cell replication, were investigated in malignant melanoma, a cancer with a paucity of effective

82 chromatin that suppresses the development of malignant melanoma, a highly intractable cutaneous neopl

83 C3), whereas 1.47 muM was observed for human malignant melanoma (A375) cells.

84 whereas an increased incidence was found for malignant melanoma among both men (SIR = 1.09) and women

85 Here we have sequenced the genomes of a malignant melanoma and a lymphoblastoid cell line from t

86 oteins such as S100B are elevated in primary malignant melanoma and are used as markers for this and

87 imple, accurate, in vivo distinction between malignant melanoma and atypical nevi, and may lead to a

88 HRH receptors in surgical specimens of human malignant melanoma and evaluated the effects of AN-207 i

89 fter diagnosis with 10 patients who survived malignant melanoma and had a median disease-free surviva

90 and the role of miRNA in the pathogenesis of malignant melanoma and identify biomarkers of metastasis

91 ve and active immunotherapy in patients with malignant melanoma and neuroblastoma.

92 EF-hand proteins that has been implicated in malignant melanoma and neurodegenerative conditions such

93 and effective role in the future control of malignant melanoma and other cancers.

94 been used to treat patients with metastatic malignant melanoma and patients rendered disease-free vi

95 ase may have broad applications for treating malignant melanoma and potentially other cancer types.

96 l relevance of different mouse Slfn genes in malignant melanoma and renal cell carcinoma cells.

97 ession of members of this family of genes in malignant melanoma and renal cell carcinoma.

98 eoplastic syndrome associated with cutaneous malignant melanoma and the presence of autoantibodies th

99 ngly implicated in the etiology of cutaneous malignant melanoma and the UV portion of the sunlight sp

100 lls, granulosa cell tumours, and a subset of malignant melanoma and thyroid cancers.

101 inhibition of RAF is already established in malignant melanoma and under investigation in non-small-

102 Their neoplastic counterparts, malignant melanomas and gliomas, have been shown in huma

103 thway), is highly expressed in primary human malignant melanomas and melanoma cell lines with activat

104 BRAF oncoprotein is mutated in about half of malignant melanomas and other cancers, and a kinase acti

105 n to evidence of multiple GISTs, lentigines, malignant melanoma, and an angioleiomyoma were identifie

106 use is associated with an increased risk of malignant melanoma, and whether any increase in risk is

107 utations occur in approximately 70% of human malignant melanomas, and a single hyperactivating V600E

108 EK-ERK pathway is deregulated in over 90% of malignant melanomas, and targeting MEK as a central kina

109 ng antibodies to augment T-cell responses to malignant melanoma are at an advanced stage; however, li

110 Highly immunogenic cancers such as malignant melanoma are capable of inexorable tumor growt

111 Hallmarks of malignant melanoma are its propensity to metastasize and

112 lignant melanoma in situ (MMIS) and invasive malignant melanoma are rising in the United States, but

113 , we report 4 cases of orbital recurrence of malignant melanoma as a late complication of biopsy and/

114 man and murine melanoma cell lines, in human malignant melanoma, as well as in metastatic melanoma in

115 rospectively evaluated the risk of cutaneous malignant melanoma associated with citrus consumption.

116 Malignant melanomas associated with good prognosis showe

117 When it escapes early detection, malignant melanoma becomes a highly lethal and treatment

118 log (NRAS) gene are common genetic events in malignant melanoma being found in 15-25% of cases.

119 on specific cancer cell lines, in particular malignant melanoma, breast cancer, and leukemia.

120 to treat metastatic renal cell carcinoma and malignant melanoma, but its use is limited by the severe

121 p53 protein complex was discovered in C8146A malignant melanoma, but the consequences of this interac

122 es, has the potential for early detection of malignant melanoma by exploiting the sensitivity and hig

123 hat PDE5 inhibitors may increase the risk of malignant melanoma by negating newly identified brakes o

124 ell degranulation, but a deleterious role in malignant melanoma, by impeding IgG1-mediated anti-tumor

125 In its early stages malignant melanoma can be cured by surgical resection, b

126 Hence, the p53 pathway in malignant melanomas can be considered for pharmacologica

127 ukin (IL)-2, a T-cell cytokine used to treat malignant melanoma, can induce profound depression.

128 For malignant melanoma cases with recorded thickness, the pr

129 atasets, which consist of 800 benign and 200 malignant melanoma cases.

130 512 that can target both the stromal and the malignant melanoma cell compartments.

131 o have significant activity in the Sk-Mel-28 malignant melanoma cell line (IC(50) values of 1.10 and

132 proliferative action of eugenol in the human malignant melanoma cell line, WM1205Lu, showed that it a

133 play essential roles in the control of mouse malignant melanoma cell proliferation and/or anchorage-i

134 ase-dependent cell death in a panel of human malignant melanoma cells (A375, G361, LOX-IMVI) but not

135 oM) and five inhibited the growth of primary malignant melanoma cells (C8146A) at comparable concentr

136 Human malignant melanoma cells (which express VEGFR-2 but not

137 FN5, SLFN11, SLFN12, SLFN13, and SLFN14), in malignant melanoma cells and primary normal human melano

138 Highly malignant melanoma cells express the highest levels of E

139 exerts potent inhibitory activities against malignant melanoma cells in vitro and in vivo, but the m

140 Down-regulation of p53 in primary malignant melanoma cells is likely the result of a direc

141 in situ contain a high level of HDAC1/2 and malignant melanoma cells overexpress HDAC1/2/3 compared

142 Importantly, stable knockdown of SLFN5 in malignant melanoma cells resulted in increased anchorage

143 logic inhibition of class I HDACs sensitizes malignant melanoma cells to apoptosis following exposure

144 e impact of class I HDACs on the response of malignant melanoma cells treated with alkylating agents.

145 gest feasibility of apoptotic elimination of malignant melanoma cells using the quinone methide-deriv

146 tional capacity of normal human melanocytes, malignant melanoma cells, and metastatic melanoma cells

147 GIGILTV) antigen expressed on the surface of malignant melanoma cells.

148 reduced KiSS-1 promoter activation in highly malignant melanoma cells.

149 EphB4 receptor and migrate faster than less malignant melanoma cells.

150 we study the phenomena of immune evasion in malignant melanoma cells.

151 Known high-risk cutaneous malignant melanoma (CMM) genes account for melanoma risk

152 The incidence of cutaneous malignant melanoma (CMM) has more than doubled in the pa

153 underlying the high prevalence of cutaneous malignant melanoma (CMM) in Parkinson disease (PD) are u

154 i (DN) is a strong risk factor for cutaneous malignant melanoma (CMM), and it frequently occurs in me

155 ion genes have been identified for cutaneous malignant melanoma (CMM), but they account for only appr

156 s locus increase susceptibility to cutaneous malignant melanoma (CMM).

157 been reproducibly associated with cutaneous malignant melanoma (CMM).

158 nmental risk factor for developing cutaneous malignant melanoma (CMM).

159 re present in approximately 50% of cutaneous malignant melanomas (CMMs).

160 factor receptor (IGF1R) is overexpressed by malignant melanomas compared with benign naevi, and medi

161 sera obtained from a subset of patients with malignant melanoma, compared with healthy control indivi

162 The incidence of cutaneous malignant melanoma continues to increase every year, and

163 Malignant melanoma continues to remain a significant hea

164 tem cell phenotype-expressing tumor cells in malignant melanoma cultures and clinical melanomas.

165 bladder cancer, renal cell cancer (RCC), and malignant melanoma data in 635 adult (>18 years of age)

166 Malignant melanoma developed within the giant nevus in 1

167 The English literature reports 16 cases of malignant melanoma developing in tattoos.

168 All 224 cases of malignant melanoma diagnosed in patients aged 10-24 year

169 In total, 1,315 incident malignant melanoma diagnoses were observed during 3.44 m

170 uired at the transition from benign nevus to malignant melanoma do not support telomere maintenance.

171 known about the role of CD82 tetraspanins in malignant melanomas during cancer cell invasion.

172 This study demonstrates that in malignant melanoma, elevated levels of nuclear beta-cate

173 Malignant melanoma exomes from 64 patients treated with

174 cancer antigens led to the recognition that malignant melanoma frequently evokes a host response.

175 Malignant melanomas harbouring point mutations (Val600Gl

176 Malignant melanoma has an unusual propensity to metastas

177 Malignant melanoma has become an increasing interdiscipl

178 The incidence of malignant melanoma has dramatically increased in recent

179 The incidence of malignant melanoma has significantly increased over the

180 f cell proliferation and drug sensitivity in malignant melanoma, holding translational potential for

181 Using tissue sections from patients with malignant melanoma, immunofluorescence studies for the p

182 between increased BMI and rectal cancer and malignant melanoma in men; postmenopausal breast, pancre

183 nt report, we evaluated the growth of B16F10 malignant melanoma in mice with a monocyte/macrophage-se

184 y, PKCalpha has been linked to metastasis of malignant melanoma in patients.

185 Cutaneous malignant melanoma in Sinclair swine is a hereditary dis

186 The incidences of malignant melanoma in situ (MMIS) and invasive malignant

187 have shown great promise in the treatment of malignant melanoma in the last few years, with these dru

188 ion was associated with an increased risk of malignant melanoma in two cohorts of women and men.

189 this peptide was selectively exposed within malignant melanoma in vivo, whereas little if any was de

190 e selective invasion and increased growth of malignant melanoma in vivo.

191 The data show that malignant melanomas in situ contain a high level of HDAC

192 shown that cyclin E is up-regulated in human malignant melanomas in vivo.

193 the role of B-Raf, the most mutated gene in malignant melanomas, in this process.

194 specific T cells in patients with metastatic malignant melanoma, indicating that the tumor-bearing st

195 Tumorigenic ABCB5(+) malignant melanoma initiating cells (MMICs) possessed th

196 erline the importance of molecularly defined malignant melanoma initiating cells for CSC-focused diag

197 Malignant melanoma-initiating cells (MMIC) are a subpopu

198 Melanoma growth is driven by malignant melanoma-initiating cells (MMIC) identified by

199 identify a subpopulation enriched for human malignant-melanoma-initiating cells (MMIC) defined by ex

200 In patients at high risk for recurrence of malignant melanoma, interferon-alpha (IFN-alpha), a stim

201 The pathogenesis of malignant melanoma involves the interplay of tumor cells

202 Malignant melanoma is a cancer that arises from melanocy

203 Late-stage malignant melanoma is a cancer that is refractory to cur

204 Malignant melanoma is a common and frequently lethal dis

205 Cutaneous malignant melanoma is a highly aggressive and frequently

206 Malignant melanoma is a highly aggressive neoplastic dis

207 Skin malignant melanoma is a highly angiogenic cancer, necess

208 sed on gene expression profiling showed that malignant melanoma is amenable to systemic treatment.

209 Metastatic malignant melanoma is an extremely aggressive cancer, wi

210 Early detection of malignant melanoma is associated with survival rates of

211 Malignant melanoma is characterized by a propensity for

212 Cutaneous malignant melanoma is considered one of the most deadly

213 le of radiotherapy for nodal metastases from malignant melanoma is controversial.

214 Evolution of conjunctival nevus into malignant melanoma is extremely low (<1%).

215 Malignant melanoma is frequently driven by mutational ac

216 The incidence of malignant melanoma is growing rapidly worldwide and ther

217 Cutaneous malignant melanoma is highly invasive and capable of met

218 -BA52 as a novel approach for the therapy of malignant melanoma is of considerable potential.

219 Cutaneous malignant melanoma is one of the fastest increasing canc

220 Malignant melanoma is one of the most aggressive human c

221 Malignant melanoma is one of the most dangerous skin can

222 Cutaneous malignant melanoma is rapidly increasing in the develope

223 Malignant melanoma is the cancer with the most rapid inc

224 Malignant melanoma is the deadliest of skin cancers.

225 or obstacle in understanding the etiology of malignant melanoma is the lack of mouse models and trans

226 Malignant melanoma is the most aggressive form of cutane

227 Malignant melanoma is the most aggressive form of skin c

228 Malignant melanoma is the most invasive and deadly form

229 Malignant melanoma is the skin cancer with the most sign

230 In malignant melanoma, its potential contribution to chemor

231 further evidence that molecular subtypes of malignant melanoma may develop along divergent pathways.

232 oma (BCC), squamous cell carcinoma (SCC), or malignant melanoma (MM) and comparative risk estimates o

233 gene is the most frequently mutated gene in malignant melanoma (MM) and papillary thyroid cancer (PT

234 A phase I study of patients with metastatic malignant melanoma (MM) and renal cell carcinoma (RCC) e

235 omplex formation with p53 ((Ca)S100B.p53) in malignant melanoma (MM) and restores p53 tumor suppresso

236 h activity in renal cell carcinoma (RCC) and malignant melanoma (MM) as single agents.

237 detection, dermatologists strive to diagnose malignant melanoma (MM) at the earliest possible stage.

238 In Denmark, the incidence of malignant melanoma (MM) has doubled during the past 25 y

239 Because fatality rates from malignant melanoma (MM) increase dramatically upon metas

240 Malignant melanoma (MM) is the most aggressive form of s

241 it sentinel lymph nodes (IMSLN) from primary malignant melanoma (MM) of the trunk.

242 In patients with lung cancer (LC), malignant melanoma (MM), gastroenteropancreatic neuroend

243 Those subsequently classified as malignant melanoma (MM), seborrheic keratosis (SK), and

244 Conditioned medium (CM) from metastatic malignant melanoma (MMM) cell lines attracted LEC migrat

245 els, including the aggressive B16F10L murine malignant melanoma model.

246 , PNL-2, and Melan-A) confirmed diagnosis of malignant melanoma of the ciliary body with extraocular

247 Fifty patients with primary malignant melanoma of the iris.

248 Malignant melanoma of the skin (CMM) is associated with

249 Malignant melanomas of the ciliary body with extraocular

250 ) lymphatic vessels were detected in 7 of 10 malignant melanomas of the ciliary body with extraocular

251 been investigated in patients with far rarer malignant melanomas of the female genital tract.

252 ther tumor lymphangiogenesis occurs in human malignant melanomas of the skin and whether the extent o

253 Malignant melanomas often harbor activating mutations in

254 Eighty patients with malignant melanoma on the trunk or extremities (upper an

255 idal tumors clinically as benign nevi versus malignant melanomas on the basis of tumor size appear li

256 consecutive days to patients with metastatic malignant melanoma or metastatic renal cell cancer.

257 othripsis with poor outcome in patients with malignant melanomas (P = 0.0002) and provides a genetic

258 ours (p=0.0046), astrocytomas (p=0.040), and malignant melanomas (p<0.0001).

259 cal significance of our results, we analyzed malignant melanoma patient samples with or without brisk

260 ased recurrence, and low overall survival in malignant melanoma patients.

261 ogen-activated protein kinase expression and malignant melanoma progression.

262 n the suppression of the HGF-MET pathway and malignant melanoma progression.

263 with histologically documented metastasized malignant melanoma received a single dose of 235 +/- 62

264 Similar to patients with malignant melanoma receiving high-dose IFN-alpha, the de

265 mechanisms underlying the intractability of malignant melanomas remain largely unknown.

266 Cutaneous malignant melanoma remains a therapeutic challenge, and

267 Metastatic malignant melanoma remains one of the most therapeutical

268 Malignant melanoma remains the deadliest form of skin ca

269 placement of tattoos and the development of malignant melanoma remains unclear.

270 Thus, a well known marker for malignant melanoma, S100B, likely contributes to cancer

271 ss is associated with a higher percentage of malignant melanoma samples with non-brisk host responses

272 suppressor activity in cancer cells such as malignant melanoma, so a search for small molecules that

273 Human malignant melanoma specimen analyses revealed a strong c

274 expressed in a very high percentage of human malignant melanoma specimens and can be used for targete

275 ivation of BRAF is a frequent event in human malignant melanomas suggesting that BRAF-dependent signa

276 We describe the first case of a malignant melanoma that developed on a preexisting nevus

277 in and beta-catenin as two of the markers of malignant melanoma that were down-regulated in Panx1-KD

278 mparative genomic hybridization (aCGH) to 20 malignant melanomas that showed, despite comparable conv

279 Although MT1-MMP is upregulated in malignant melanoma, the biological consequences of eleva

280 ion and the possible clinical implication on malignant melanoma therapy with temozolomide and other a

281 Consistently, Brca1 loss in human malignant melanoma tissues was found to be inversely cor

282 ping roles for these genes in the control of malignant melanoma tumorigenesis.

283 n progenitor cells, is expressed in clinical malignant melanoma tumors and preferentially marks a sub

284 MSH), has the potential for the detection of malignant melanoma using PET.

285 omas versus benign seborrheic keratoses; and malignant melanomas versus benign nevi.

286 ific in vivo targeting of (18)F-FB-RMSH-1 to malignant melanoma was successfully achieved in preclini

287 mber of individuals with two or more primary malignant melanomas was not detected among the groups (P

288 Finally, using a model of malignant melanoma, we show that the oncogenic potential

289 node or in-transit metastasis from cutaneous malignant melanoma were randomly assigned to receive eit

290 ity criteria, only a few aspects--limited to malignant melanoma--were adaptable.

291 ble for the induction of mammalian cutaneous malignant melanoma whereas UVA is ineffective even at do

292 olet light exposure, a known risk factor for malignant melanoma, whereas the uneven distribution of m

293 We describe a patient with malignant melanoma who developed chronic lymphocytic leu

294 0201 patients at high risk for recurrence of malignant melanoma who received prolonged immunization w

295 to metastasize to the small bowel; however, malignant melanoma with metastatic spread to the appendi

296 al responses achieved by treating metastatic malignant melanoma with therapeutic modalities based on

297 and DGKI-BRAF fusion were identified in two malignant melanomas with a low mutational burden (number

298 or chromosome arm gains and losses, whereas malignant melanomas with poor prognosis harbored signifi

299 In all cases, histopathology confirmed malignant melanoma, with no intraepithelial component or

300 a steady rise in the incidence of cutaneous malignant melanoma worldwide.